Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice.

Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J, Irie K, Holle E, Yu X, Kupershmidt S, Roden DM, Wagner T, Yatani A, Vatner DE, Vatner SF, Sadoshima J.

J Clin Invest. 2005 Nov;115(11):3045-56.

2.

Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling.

Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P.

J Clin Invest. 2005 Sep;115(9):2508-16.

3.

Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system.

Crowley SD, Gurley SB, Oliverio MI, Pazmino AK, Griffiths R, Flannery PJ, Spurney RF, Kim HS, Smithies O, Le TH, Coffman TM.

J Clin Invest. 2005 Apr;115(4):1092-9.

4.

Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma.

Vecchione C, Patrucco E, Marino G, Barberis L, Poulet R, Aretini A, Maffei A, Gentile MT, Storto M, Azzolino O, Brancaccio M, Colussi GL, Bettarini U, Altruda F, Silengo L, Tarone G, Wymann MP, Hirsch E, Lembo G.

J Exp Med. 2005 Apr 18;201(8):1217-28. Epub 2005 Apr 11.

5.

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.

Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K.

Circulation. 2004 Sep 14;110(11):1456-62. Epub 2004 Aug 23.

6.

Exploring type I angiotensin (AT1) receptor functions through gene targeting.

Crowley SD, Tharaux PL, Audoly LP, Coffman TM.

Acta Physiol Scand. 2004 Aug;181(4):561-70. Review.

PMID:
15283771
7.

Role for thromboxane receptors in angiotensin-II-induced hypertension.

Francois H, Athirakul K, Mao L, Rockman H, Coffman TM.

Hypertension. 2004 Feb;43(2):364-9. Epub 2004 Jan 12.

8.

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee.

Hypertension. 2003 Dec;42(6):1206-52. Epub 2003 Dec 1.

9.

Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure.

Tang KM, Wang GR, Lu P, Karas RH, Aronovitz M, Heximer SP, Kaltenbronn KM, Blumer KJ, Siderovski DP, Zhu Y, Mendelsohn ME.

Nat Med. 2003 Dec;9(12):1506-12. Epub 2003 Nov 9. Erratum in: Nat Med. 2004 Jan;10(1):105. Tang, Mary [corrected to Tang, K Mary]; Wang, Guang [corrected to Wang, Guang-rong].

PMID:
14608379
10.

Regulation of sodium transporters in the thick ascending limb of rat kidney: response to angiotensin II.

Kwon TH, Nielsen J, Kim YH, Knepper MA, Frøkiaer J, Nielsen S.

Am J Physiol Renal Physiol. 2003 Jul;285(1):F152-65. Epub 2003 Mar 25.

11.

Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT(1) receptors.

Peti-Peterdi J, Warnock DG, Bell PD.

J Am Soc Nephrol. 2002 May;13(5):1131-5.

12.

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group.

Lancet. 2002 Mar 23;359(9311):995-1003.

PMID:
11937178
13.

Molecular phenotyping for analyzing subtle genetic effects in mice: application to an angiotensinogen gene titration.

Kim HS, Lee G, John SW, Maeda N, Smithies O.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4602-7. Epub 2002 Mar 19.

14.

Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice.

Bendall JK, Cave AC, Heymes C, Gall N, Shah AM.

Circulation. 2002 Jan 22;105(3):293-6.

15.

Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta.

Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, Smithies O, Gustafsson JA, Mendelsohn ME.

Science. 2002 Jan 18;295(5554):505-8.

16.

Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.

Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J.

Hypertension. 2001 Dec 1;38(6):E28-32.

17.

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.

Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators.

Circulation. 2001 Oct 2;104(14):1615-21.

18.
19.
20.

Molecular mechanisms of human hypertension.

Lifton RP, Gharavi AG, Geller DS.

Cell. 2001 Feb 23;104(4):545-56. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk